Author pages are created from data sourced from our academic publisher partnerships and public sources.
Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder
- Morihiro Fujimura, N. Izumimoto, +9 authors K. Kawai
- Chemistry, Medicine
- The Journal of Pharmacology and Experimental…
- 1 September 2014
We characterized TRK-130 (N-[(5R,6R,14S)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]phthalimide; naltalimide), an opioid ligand, to clarify the therapeutic potential for overactive… Expand
Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex
- Morihiro Fujimura, N. Izumimoto, +11 authors K. Kawai
- International Urology and Nephrology
- 16 January 2017
PurposeTo clarify the mechanism of inhibitory action of TRK-130 (Naltalimide), a unique µ-opioid receptor partial agonist, on the micturition reflex.MethodsThe effect of TRK-130 on isovolumetric… Expand
A next generation drug for Overactive bladder, TRK-130, in a Phase-IIb clinical trial in Japan; Preclinical data of potent pharmacological effects based on modulation of neurotransmission.
Hypothesis / aims of study It has been well-known that opioidergic modulation involves in the control of voiding pathway through spinal and supraspinal mechanism 1) . Therefore, opioid receptor… Expand